Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:COYA NASDAQ:PMN NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.69-1.7%$1.85$1.07▼$6.18$103.75M1.161.98 million shs1.17 million shsCOYACoya Therapeutics$4.54-1.3%$4.98$3.71▼$7.75$107.90M0.51256,782 shs360,880 shsPMNPromis Neurosciences$15.19+14.2%$11.32$6.27▼$39.75$119.27M-0.2365,982 shs132,985 shsSNTISenti Biosciences$0.44-4.9%$0.96$0.42▼$2.88$14.32M2.04335,328 shs406,241 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-1.74%-18.36%-7.65%-6.11%-67.25%COYACoya Therapeutics-1.30%-13.69%-9.74%-5.02%-21.59%PMNPromis Neurosciences+14.21%+6.60%+46.34%+31.74%+35.02%SNTISenti Biosciences-5.00%-57.57%-54.04%-60.27%-77.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.69-1.7%$1.85$1.07▼$6.18$103.75M1.161.98 million shs1.17 million shsCOYACoya Therapeutics$4.54-1.3%$4.98$3.71▼$7.75$107.90M0.51256,782 shs360,880 shsPMNPromis Neurosciences$15.19+14.2%$11.32$6.27▼$39.75$119.27M-0.2365,982 shs132,985 shsSNTISenti Biosciences$0.44-4.9%$0.96$0.42▼$2.88$14.32M2.04335,328 shs406,241 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-1.74%-18.36%-7.65%-6.11%-67.25%COYACoya Therapeutics-1.30%-13.69%-9.74%-5.02%-21.59%PMNPromis Neurosciences+14.21%+6.60%+46.34%+31.74%+35.02%SNTISenti Biosciences-5.00%-57.57%-54.04%-60.27%-77.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50225.44% UpsideCOYACoya Therapeutics 2.71Moderate Buy$15.33237.74% UpsidePMNPromis Neurosciences 2.86Moderate Buy$24.0058.00% UpsideSNTISenti Biosciences 2.75Moderate Buy$10.002,188.33% UpsideCurrent Analyst Ratings BreakdownLatest SNTI, ALDX, PMN, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/7/2026PMNPromis Neurosciences Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.007/7/2026PMNPromis Neurosciences Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/30/2026PMNPromis Neurosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/24/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/12/2026COYACoya Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.006/11/2026PMNPromis Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026PMNPromis Neurosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/8/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/5/2026COYACoya Therapeutics Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/20/2026ALDXAldeyra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.74 per shareN/ACOYACoya Therapeutics$7.95M13.40N/AN/A$2.06 per share2.20PMNPromis NeurosciencesN/AN/AN/AN/A($0.58) per shareN/ASNTISenti Biosciences$20K680.63N/AN/A$0.18 per share2.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%8/6/2026 (Estimated)COYACoya Therapeutics-$21.23M-$1.15N/AN/AN/A-266.10%-55.86%-48.86%8/11/2026 (Estimated)PMNPromis Neurosciences-$39.72M-$14.51N/AN/AN/AN/A-237.99%-151.04%8/12/2026 (Estimated)SNTISenti Biosciences-$61.44M-$1.92N/AN/AN/AN/A-532.05%-103.35%8/6/2026 (Estimated)Latest SNTI, ALDX, PMN, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026PMNPromis Neurosciences-$1.45N/AN/AN/AN/AN/A8/11/2026Q2 2026COYACoya Therapeutics-$0.36N/AN/AN/A$0.13 millionN/A8/6/2026Q2 2026ALDXAldeyra Therapeutics-$0.11N/AN/AN/A$31.33 millionN/A8/6/2026Q2 2026SNTISenti Biosciences-$0.33N/AN/AN/A$0.02 millionN/A5/14/2026Q1 2026SNTISenti Biosciences-$0.36-$0.14+$0.22-$0.14$0.02 million$0.02 million5/12/2026Q1 2026COYACoya Therapeutics-$0.39-$0.32+$0.07-$0.32$0.15 million$0.25 million5/12/2026Q1 2026PMNPromis Neurosciences-$1.06-$1.26-$0.20-$1.26N/AN/A5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72COYACoya TherapeuticsN/A15.0215.02PMNPromis NeurosciencesN/A9.929.92SNTISenti BiosciencesN/A1.041.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%COYACoya Therapeutics39.75%PMNPromis Neurosciences50.13%SNTISenti Biosciences25.70%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics11.80%COYACoya Therapeutics6.10%PMNPromis Neurosciences1.50%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million53.20 millionOptionableCOYACoya Therapeutics623.46 million22.03 millionNot OptionablePMNPromis Neurosciences58.97 million8.83 millionNot OptionableSNTISenti Biosciences431.15 million30.17 millionNot OptionableSNTI, ALDX, PMN, and COYA HeadlinesRecent News About These CompaniesSenti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...July 15 at 8:13 AM | markets.businessinsider.comSenti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology PlatformJuly 15 at 7:30 AM | globenewswire.comSenti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note StructureMay 16, 2026 | tipranks.comSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...May 14, 2026 | markets.businessinsider.comSenti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid LeukemiaMay 14, 2026 | quiverquant.comQSenti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal PhaseMay 14, 2026 | globenewswire.comSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical ProgramMay 14, 2026 | globenewswire.comSenti Biosciences Holdings Inc.May 13, 2026 | barrons.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | markets.businessinsider.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | globenewswire.comSenti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell TherapiesApril 1, 2026 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateMarch 27, 2026 | globenewswire.comSenti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer ConferenceMarch 23, 2026 | globenewswire.comSenti Biosciences Amends Lease, Restructures GeneFab SubleaseMarch 19, 2026 | tipranks.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | tmcnet.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comSenti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care ConferenceFebruary 24, 2026 | quiverquant.comQSenti Biosciences to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 24, 2026 | globenewswire.comSenti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy DevelopmentFebruary 20, 2026 | globenewswire.comSenti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)February 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNTI, ALDX, PMN, and COYA Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.69 -0.03 (-1.74%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$1.68 0.00 (-0.30%) As of 07/17/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Coya Therapeutics NASDAQ:COYA$4.54 -0.06 (-1.30%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$4.55 +0.01 (+0.31%) As of 07/17/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Promis Neurosciences NASDAQ:PMN$15.19 +1.89 (+14.21%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$15.08 -0.10 (-0.69%) As of 07/17/2026 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Senti Biosciences NASDAQ:SNTI$0.44 -0.02 (-4.94%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.44 +0.01 (+1.37%) As of 07/17/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
